<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>International Journal of Reproductive BioMedicine</title>
<title_fa>International Journal of Reproductive BioMedicine</title_fa>
<short_title>IJRM</short_title>
<subject>Medical Sciences</subject>
<web_url>http://ijrm.ir</web_url>
<journal_hbi_system_id>1</journal_hbi_system_id>
<journal_hbi_system_user>admin</journal_hbi_system_user>
<journal_id_issn>2476-4108</journal_id_issn>
<journal_id_issn_online>2476-3772</journal_id_issn_online>
<journal_id_pii></journal_id_pii>
<journal_id_doi>10.29252/ijrm</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid></journal_id_sid>
<journal_id_nlai></journal_id_nlai>
<journal_id_science></journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1386</year>
	<month>4</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2007</year>
	<month>7</month>
	<day>1</day>
</pubdate>
<volume>5</volume>
<number>3</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>CA-125 in normal pregnancy and threatened abortion</title>
	<subject_fa></subject_fa>
	<subject></subject>
	<content_type_fa>Original Article</content_type_fa>
	<content_type>Original Article</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;strong&gt;Background:&lt;/strong&gt; CA-125 is a glycoprotein and its origin is uncertain during pregnancy. It arises during the first trimester and return to a non-pregnancy range in late pregnancy.&lt;br&gt;
&lt;strong&gt;Objective:&lt;/strong&gt; The aim of this study was to compare CA-125 level in threatened abortion and normal pregnancy less than 20 weeks of pregnancy.&lt;br&gt;
&lt;strong&gt;Materials and Methods:&lt;/strong&gt; This was a prospective case study carried out on 50 healthy pregnant (group 1) and 50 threatened abortion women (group 2). We compared the levels of CA-125 in these groups and followed them to be informed of the outcome of pregnancy.&lt;br&gt;
&lt;strong&gt;Results:&amp;nbsp;&lt;/strong&gt;Fifty percent of women were in 20-24 years old group, primigravida and in the first trimester of pregnancy. The mean level of CA-125 in group 1 was 26.2 &amp;plusmn; 3.25 IU/ml and in group 2 was 37.44 &amp;plusmn; 2.72 IU/ml. The mean level of CA-125 in finally aborted patients was 58.17&amp;plusmn;7.25 IU/ml and in normal pregnant women, who continue to term, was 26.61&amp;plusmn;1.76 IU/ml. The CA-125 level in threatened women,whose pregnancy continued and did not abort, was 30.89 IU/ml. There was statistically significant difference between mean serum CA-125 levels of two groups (&lt;em&gt;p&lt;/em&gt; &lt; 0.05), while there was no statistically significant difference between these levels in the patients of both groups who continued pregnancies (&lt;em&gt;p &lt;/em&gt;&gt; 0.1). In group 2, there was a statistically significant difference in the level of CA-125 between those who developed abortion and those whose pregnancy continued but not aborted (&lt;em&gt;p&lt;/em&gt; &lt; 0.05).&lt;br&gt;
&lt;strong&gt;Conclusion: &lt;/strong&gt;Measurement of serum CA-125 may be an inexpensive, easily available, sensitive and specific predictor of outcome in threatened abortion, which results the loss of pregnancy.</abstract>
	<keyword_fa></keyword_fa>
	<keyword>CA-125, Pregnancy, Abortion, Threatened abortion</keyword>
	<start_page>57</start_page>
	<end_page>0</end_page>
	<web_url>http://ijrm.ir/browse.php?a_code=A-10-549-278&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Sedigheh</first_name>
	<middle_name></middle_name>
	<last_name>Ayaty</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>ff_vahid @ yahoo.com</email>
	<code></code>
	<orcid></orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Ghaem Hospital-Mashhad University of Medical Sciences, Mashhad, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Fatemeh</first_name>
	<middle_name></middle_name>
	<last_name>Vahid Roudsari</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code></code>
	<orcid></orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Ghaem Hospital-Mashhad University of Medical Sciences, Mashhad, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Fatemeh</first_name>
	<middle_name></middle_name>
	<last_name>Tavassoly</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code></code>
	<orcid></orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
